GHRYVELIN (previously Macimorelin Aeterna Zentaris)

Ghryvelin is available as granules that are dissolved in water and taken by mouth. The recommended dose is 0.5 mg per kg body weight which the patient should take once. The doctor then takes blood samples 45, 60 and 90 minutes later to see how much growth hormone the body has produced.

Ghryvelin can only be obtained with a prescription and its use must be supervised by a healthcare professional experienced in diagnosing growth hormone deficiency. For more information about using GHRYVELIN, see the package leaflet or contact your doctor or pharmacist.

The active substance in Ghryvelin, macimorelin, stimulates the release of growth hormone into the blood by activating receptors (targets) found on cells in the pituitary gland, a gland located at the base of the brain. The level of growth hormone in the blood is then measured and indicates whether or not the body is able to produce growth hormone.

Ghryvelin was compared with another test commonly used to diagnose growth hormone deficiency, called insulin tolerance test (ITT), in one main study.

The study involved 166 adults who had either a high, intermediate or low likelihood of having growth hormone deficiency, or who were confirmed not to have growth hormone deficiency. Among them, 140 were tested with both Ghryvelin and ITT.

Overall, 94% of people who tested negative for growth hormone deficiency with ITT also tested negative with Ghryvelin; 74% of people who tested positive with ITT also tested positive with Ghryvelin. This means that, although Ghryvelin might not diagnose all cases of disease, it can help to confirm presence of the disease.

The most common side effects with Ghryvelin (which may affect up to 1 in 10 people) are a bitter or metallic taste, tiredness, headache, nausea (feeling sick), dizziness, diarrhoea and feeling hot. Ghryvelin may also cause a change in heart rhythm. Overall, the side effects were mostly mild and short-lasting, with no need for a specific treatment.

For the full list of side effects and restrictions with Ghryvelin, see the package leaflet.

Ghryvelin gave a similar number of negative test results for growth hormone deficiency as a comparator test; however, it gives fewer positive test results than the comparator. EMA considered that it is a priority to avoid over-diagnosis of adult growth hormone deficiency and that Ghryvelin helps confirm positive diagnosis and so avoid unnecessary treatment of patients with a false positive test result.

In terms of safety, the main concern was that the medicine may change heart rhythm. However this risk is considered small as patients take only one dose of the medicine and are supervised by their doctor. On the whole, Ghryvelin has fewer side effects than the comparator test, which temporarily lowers the level of sugar in the blood.

EMA therefore decided that Ghryvelin's benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ghryvelin have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ghryvelin are continuously monitored. Side effects reported with Ghryvelin are carefully evaluated and any necessary action taken to protect patients.

Ghryvelin received a marketing authorisation valid throughout the EU on 11 January 2019.

GHRYVELIN is available as granules that are dissolved in water and taken by mouth. The recommended dose is 0.5 mg per kg body weight which the patient should take once. The doctor then takes blood samples 45, 60 and 90 minutes later to see how much growth hormone the body has produced.

GHRYVELIN can only be obtained with a prescription and its use must be supervised by a healthcare professional experienced in diagnosing growth hormone deficiency. For more information about using GHRYVELIN, see the package leaflet or contact your doctor or pharmacist.

The active substance in GHRYVELIN, macimorelin, stimulates the release of growth hormone into the blood by activating receptors (targets) found on cells in the pituitary gland, a gland located at the base of the brain. The level of growth hormone in the blood is then measured and indicates whether or not the body is able to produce growth hormone.

GHRYVELIN was compared with another test commonly used to diagnose growth hormone deficiency, called insulin tolerance test (ITT), in one main study.

The study involved 166 adults who had either a high, intermediate or low likelihood of having growth hormone deficiency, or who were confirmed not to have growth hormone deficiency. Among them, 140 were tested with both GHRYVELIN and ITT.

Overall, 94% of people who tested negative for growth hormone deficiency with ITT also tested negative with GHRYVELIN; 74% of people who tested positive with ITT also tested positive with GHRYVELIN. This means that, although GHRYVELIN might not diagnose all cases of disease, it can help to confirm presence of the disease.

The most common side effects with GHRYVELIN (which may affect up to 1 in 10 people) are a bitter or metallic taste, tiredness, headache, nausea (feeling sick), dizziness, diarrhoea and feeling hot. GHRYVELIN may also cause a change in heart rhythm. Overall, the side effects were mostly mild and short-lasting, with no need for a specific treatment.

For the full list of side effects and restrictions with GHRYVELIN, see the package leaflet.

GHRYVELIN gave a similar number of negative test results for growth hormone deficiency as a comparator test; however, it gives fewer positive test results than the comparator. EMA considered that it is a priority to avoid over-diagnosis of adult growth hormone deficiency and that GHRYVELIN helps confirm positive diagnosis and so avoid unnecessary treatment of patients with a false positive test result.

In terms of safety, the main concern was that the medicine may change heart rhythm. However this risk is considered small as patients take only one dose of the medicine and are supervised by their doctor. On the whole, GHRYVELIN has fewer side effects than the comparator test, which temporarily lowers the level of sugar in the blood.

EMA therefore decided that GHRYVELIN's benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of GHRYVELIN have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of GHRYVELIN are continuously monitored. Side effects reported with GHRYVELIN are carefully evaluated and any necessary action taken to protect patients.

GHRYVELIN received a marketing authorisation valid throughout the EU on 11 January 2019.